Following its success in other leukemias, though venetoclax only showed modest single-agent activity in AML, strong preclinical data suggesting increased expression of BCL-2 and MCL1 in AML and the possibility of indirectly targeting MCL1 with cytotoxic drugs kept the researchers going [46]. Here, BCL2 is linked to acute myeloid leukemia.